Latisse, which is the first and only prescription treatment approved by the FDA to grow lashes longer, fuller and darker, recently unveiled before and after photos of its latest celebrity spokesperson, actress Claire Danes. She follows in footsteps of Brooke Shields as a spokesmodel for the lash grower.
Throughout her 16-week treatment on Lastisse, Danes was photographed at different angles to demonstrate her lash growth. The gallery is posted on the Latisse site and none of the photos have been retouched.
Danes said she became the latest “Latisse girl” because she was curious about the product. “The more I learned about Latisse, the more impressed I was. I’ve never used a product that actually affected real physical change,” she said.
In 2001, Allergan developed a glaucoma treatment called Lumigan, and a side effect was discovered—patients began growing longer, fuller lashes. This led Allergan to study the active ingredient in this other product, and after a clinical trial, Latisse was born and earned FDA approval in December 2008.
During research of Latisse, doctors reported on average:
- 25 percent increase in eyelash length
- 106 percent increase in eyelash fullness
- 18 percent darkening of the eyelashes
The effects of Latisse are not permanent, so you have to keep using it, as the eyelashes will return to normal if you stop using Latisse. Advancements in Dermatology offers Lastisse; call for more information and special introductory pricing. You can sign up for Latisse Lash Perks to get a $20 rebate on Latisse. (images via www.latisse.com)
developed and used as a glaucoma medication. In using the medication, many patients noticed that their eyelashes grew significantly, to the point that some even felt the need to trim them. Allergan, who owned the medication, began to market it as Latisse, for topical use in patients with “inadequate eyelashes.”
